Shengwen Calvin L.
Associate Editor, Section Editor, Cancer Control (if 3 429) @Sage
Signup · Get unlimited contacts
WORK HISTORY
Associate Editor, Section Editor, Cancer Control (if 3 429) @Sage
London, GB
Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.https://journals.sagepub.com/editorial-board/CCX
EDUCATION
Massachusetts Institute of Technology
Certificate of Completion, Professional, Technical, Business, and Scientific Writing
Harvard Medical School
Research Fellowship
The City University of New York
student and research assistant, Queens College, Dept. of Biology, Behavioral Sciences, ecology, evolution biology
UC Irvine
NIH Training Course, Human Embryonic Stem Cell Culture
Icahn School of Medicine at Mount Sinai
Doctor of Philosophy (PhD), Biomedical Sciences, General
UC Irvine
Certificate of Completion, Certificate Program in Project and Program Management
The City University of New York
student and research assistant,CCNY, Department of Biochemistry and Chemistry, Molecular Biology, enzyme replacement therapy
Massachusetts Institute of Technology
Postdoc NRSA Fellow
University Clinical Investigation Training Program - CITP
Certificate of Completion, Clinical Investigation
Icahn School of Medicine at Mount Sinai
PhD, BIOLOGICAL AND BIOMEDICAL SCIENCES
ABOUT SHENGWEN CALVIN L.
Inductee to Sigma Xi (FSX), The Scientific Research Honor Society (founded in 1886), pledged and committed to bettering the world through Science & Technology. PhD: Mount Sinai School of Medicine; Postdoc: Whitehead Institute/MIT; Fellowship: Harvard Medical School. Editor-in-Chief, World J. Stem Cells (IF 5.326, 2020). FRSB, FRSM. 154+ publications and 20+ USPTO-issued patents. His work is among the most-frequently-cited (single papers with citations), and remarked in Nature, Cell, and Ann Rev. Cell & Dev. Biol. Editorial board membership with PLOS One (Academic Editor, 2018-), American J. Pathology (ASIP, Elsevier, 20••••16), Curr. Stem Cell Res. & Therapy (Bentham Publishing (U.A.E, 2015-), Medical Sciences (MDPI Inc, Switzerland, 2018-), Associated Editor of Frontier in Oncology (Switzerland), Section Editor of Cancer Control (SAGE, U.K.), & J. Cell Sci. & Therapy (2012-). Ad-hoc reviewer for grant agencies. Principal Investigator for research projects. Adjunct Professor teaching at University. Founder, biotechnology companies. with membership of ACTS, ISSCR, SfN, ASCB, ASN, ASIP, and elected overseas fellow to the Royal Society of Medicine (RSM, UK) and the Royal Society of Biology. Specialties: therapeutic development for diabetes and obesity, immunotherapy, pharmacology, brain tumor bank, brain tumor stem cell line banking, cancer models, 3-D cell culture, organotypic culture, engineered tissue graft model; stem cell therapy, cancer genome, single-cell transcriptomes.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.